Caris Life Sciences Introduces AI Tool to Predict Chemotherapy Resistance in Ovarian Cancer

MT Newswires Live

Mar 16

Caris Life Sciences (CAI) said Monday it has launched an artificial intelligence tool designed to help doctors predict whether patients with high-grade serous ovarian cancer, or HGSOC, will become resistant to platinum-based chemotherapy.

The tool is part of the company's Caris AI Insights platform. It identifies molecular patterns linked to platinum resistance and generates a risk score and a prediction of whether the cancer is likely to be platinum-sensitive or platinum-resistant, the company said.

The tool is available through the Caris Molecular Tumor Board Report when ordering the Caris' tissue-based cancer test, MI Cancer Seek, the company added.

Shares of Caris Life Sciences rose nearly 3.5% in the session.

Price: 18.79, Change: +0.64, Percent Change: +3.53

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2619464873"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2619464873\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2619464873?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 22:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619464873","market":"hk","top_or_hot":-1,"title":"Caris Life Sciences Introduces AI Tool to Predict Chemotherapy Resistance in Ovarian Cancer","media":"MT Newswires Live","content":"<html><body><p> Caris Life Sciences (CAI) said Monday it has launched an artificial intelligence tool designed to help doctors predict whether patients with high-grade serous ovarian cancer, or HGSOC, will become resistant to platinum-based chemotherapy.</p><p>The tool is part of the company's Caris AI Insights platform. It identifies molecular patterns linked to platinum resistance and generates a risk score and a prediction of whether the cancer is likely to be platinum-sensitive or platinum-resistant, the company said.</p><p>The tool is available through the Caris Molecular Tumor Board Report when ordering the Caris' tissue-based cancer test, MI Cancer Seek, the company added.</p><p>Shares of Caris Life Sciences rose nearly 3.5% in the session.</p><p>Price: 18.79, Change: +0.64, Percent Change: +3.53</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caris Life Sciences Introduces AI Tool to Predict Chemotherapy Resistance in Ovarian Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaris Life Sciences Introduces AI Tool to Predict Chemotherapy Resistance in Ovarian Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-16 22:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Caris Life Sciences (CAI) said Monday it has launched an artificial intelligence tool designed to help doctors predict whether patients with high-grade serous ovarian cancer, or HGSOC, will become resistant to platinum-based chemotherapy.</p><p>The tool is part of the company's Caris AI Insights platform. It identifies molecular patterns linked to platinum resistance and generates a risk score and a prediction of whether the cancer is likely to be platinum-sensitive or platinum-resistant, the company said.</p><p>The tool is available through the Caris Molecular Tumor Board Report when ordering the Caris' tissue-based cancer test, MI Cancer Seek, the company added.</p><p>Shares of Caris Life Sciences rose nearly 3.5% in the session.</p><p>Price: 18.79, Change: +0.64, Percent Change: +3.53</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7104","symbol_name":"黄金","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2619464873","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2619464873","pubTimestamp":1773672125,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Caris Life Sciences  said Monday it has launched an artificial intelligence tool designed to help doctors predict whether patients with high-grade serous ovarian cancer, or HGSOC, will become resistant to platinum-based chemotherapy.The tool is part of the company's Caris AI Insights platform. It identifies molecular patterns linked to platinum resistance and generates a risk score and a prediction of whether the cancer is likely to be platinum-sensitive or platinum-resistant, the company said.The tool is available through the Caris Molecular Tumor Board Report when ordering the Caris' tissue-based cancer test, MI Cancer Seek, the company added.Shares of Caris Life Sciences rose nearly 3.5% in the session.Price: 18.79, Change: +0.64, Percent Change: +3.53","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7104":"黄金","PLTM":"GraniteShares Platinum Trust","CAI.AU":"CALIDUS RESOURCES LTD","BK4139":"生物科技","BK4104":"贸易公司与经销商","CAI":"Caris Life Sciences, Inc."},"translate_title":"Caris Life Sciences推出人工智能工具预测卵巢癌化疗耐药性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAI":1.5,"PLTM":0.78,"CAI.AU":1},"content_text":"Caris Life Sciences (CAI) said Monday it has launched an artificial intelligence tool designed to help doctors predict whether patients with high-grade serous ovarian cancer, or HGSOC, will become resistant to platinum-based chemotherapy.The tool is part of the company's Caris AI Insights platform. It identifies molecular patterns linked to platinum resistance and generates a risk score and a prediction of whether the cancer is likely to be platinum-sensitive or platinum-resistant, the company said.The tool is available through the Caris Molecular Tumor Board Report when ordering the Caris' tissue-based cancer test, MI Cancer Seek, the company added.Shares of Caris Life Sciences rose nearly 3.5% in the session.Price: 18.79, Change: +0.64, Percent Change: +3.53","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}